Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Neoadjuvant Therapy for Rectal Cancer
NCT06758830Phase 3Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, fluorouracil, oxaliplatin, folinic acid in rectal cancer. Started Jan 2025; status: recruiting.
02
Drugs
capecitabinefluorouraciloxaliplatinfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06758830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758830.